
Sign up to save your podcasts
Or


Eli Lilly shares rise after the drugmaker said on Friday that the FDA approved its weight-loss drug Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Xerox shares finish higher after the company struck a $1.5 billion deal to buy printer maker Lexmark. J.R. Whalen reports.
Programming note: Minute Briefing will release its next episode midday Tuesday.
Sign up for the WSJ's free What's News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
By The Wall Street Journal4.2
652652 ratings
Eli Lilly shares rise after the drugmaker said on Friday that the FDA approved its weight-loss drug Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Xerox shares finish higher after the company struck a $1.5 billion deal to buy printer maker Lexmark. J.R. Whalen reports.
Programming note: Minute Briefing will release its next episode midday Tuesday.
Sign up for the WSJ's free What's News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices

2,835 Listeners

1,720 Listeners

4,345 Listeners

404 Listeners

420 Listeners

1,657 Listeners

1,425 Listeners

1,038 Listeners

1,302 Listeners

6,089 Listeners

1,561 Listeners

213 Listeners

1,322 Listeners

586 Listeners

151 Listeners

85 Listeners

80 Listeners

142 Listeners